🔍

GRANULES - Granules India

📊 NSE: GRANULES 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 22:34

📢 Recent Corporate Announcements

Granules India's US Packaging Facility Receives US FDA EIR with NAI Status

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 05 Mar 2026, 11:41 AM

Granules India's US subsidiary, Granules Consumer Health, LLC, has received an Establishment Inspection Report (EIR) with 'No Action Indicated' (NAI) status from the US FDA. The inspection was conducted at its Manassas, Virginia packaging facility between December 1 and 3, 2025. This marks the second consecutive time the facility has cleared an FDA audit with zero observations, following a similar result in March 2023. The facility serves as a critical distribution hub for the company's US front-end OTC and prescription product operations.

Received US FDA EIR with No Action Indicated (NAI) status for the Virginia packaging facility.
The inspection was conducted from December 1 to 3, 2025, resulting in zero observations.
Second consecutive successful FDA audit for this facility following the March 2023 inspection.
The site operates three advanced packaging lines for OTC and prescription (Rx) products.
Facility handles controlled substances and serves as a primary US distribution hub.

💡 This regulatory clearance confirms Granules' strong compliance culture and ensures no supply chain disruptions for its US OTC business. Investors should maintain a positive outlook on the stock given its consistent track record of zero-observation audits.

Granules India to Attend UBS Emerging India Mid-Caps Corporate Day in Singapore

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 02 Mar 2026, 03:42 PM

Granules India Limited has scheduled meetings with analysts and institutional investors on March 9 and 10, 2026. The company will be participating in the UBS Emerging India Mid-Caps Corporate Day held in Singapore. The engagement will include both one-to-one and group meeting formats to discuss company performance based on publicly available information. Such international roadshows are standard practices to increase visibility among foreign institutional investors.

Event scheduled for March 09, 2026, and March 10, 2026, in Singapore.
Participation in the UBS Emerging India Mid-Caps Corporate Day.
Meeting formats include both one-to-one and group interactions with funds.
Company confirmed that no unpublished price-sensitive information (UPSI) will be shared.
The latest investor presentation remains the primary document for discussion.

💡 No immediate action is required as this is a routine investor relations activity. Investors should monitor for any significant shifts in institutional shareholding in the upcoming quarter.

Granules India Allots Equity and Warrants Worth Rs 1,762.5 Cr at Rs 585/Share

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 23 Feb 2026, 05:03 PM

Granules India has successfully allotted 51.28 lakh equity shares to institutional investors and 2.5 crore convertible warrants to the promoter group and select non-promoters. The allotment was priced at Rs 585 per share/warrant, with the company immediately raising Rs 300 crore from equity and Rs 365.6 crore as a 25% upfront warrant payment. This significant capital infusion, largely backed by the promoter group, indicates strong internal confidence and provides a substantial war chest for future growth. On a fully diluted basis, the total share capital will increase to 27.28 crore shares.

Allotted 51,28,205 equity shares at Rs 585 each, raising Rs 300 crore from 360 ONE institutional funds.
Issued 2,50,00,000 convertible warrants at Rs 585 each, with 25% (Rs 365.62 crore) received upfront.
Promoter group subscribed to the majority of warrants, with Mrs. Chigurupati Uma Devi taking 2.48 crore warrants.
Total potential capital to be raised via warrants is Rs 1,462.5 crore within an 18-month conversion window.
Paid-up equity capital increased to Rs 24.78 crore and will reach Rs 27.28 crore on a fully diluted basis.

💡 Investors should view the promoter participation at Rs 585 as a strong signal of confidence in the company's valuation and future prospects. Monitor upcoming quarterly results for commentary on how this capital will be deployed for expansion or debt management.

Granules India to Issue 2.5 Cr Warrants and 51.28 Lakh Equity Shares via Preferential Issue

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 06 Feb 2026, 02:46 PM

Granules India has received shareholder approval for a significant fundraise through a preferential issue of securities. The company plans to issue up to 2,50,00,000 convertible warrants and 51,28,205 equity shares to specific investors. The pricing will be subject to recomputation as per SEBI ICDR Regulations if required. Until the proceeds are fully utilized for their intended objects, the funds will be parked in low-risk instruments like debt mutual funds and government securities.

Authorized issuance of up to 2,50,00,000 warrants convertible into equity shares
Authorized issuance of up to 51,28,205 equity shares on a preferential basis
Shareholder approval for the resolutions was obtained in the EGM held on January 22, 2026
Pricing of securities to be recomputed in compliance with SEBI ICDR Regulations where necessary
Unutilized proceeds to be temporarily invested in debt mutual funds, bank deposits, or government securities

💡 Investors should track the final allotment price and the specific end-use of funds to assess the long-term growth potential versus equity dilution. The move indicates a strong intent to raise capital for expansion or balance sheet strengthening.

Granules India Q3 FY26: Revenue Up 22% to ₹1,388 Cr, EBITDA Grows 34% with Margin Expansion

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 28 Jan 2026, 03:21 PM

Granules India reported a strong Q3 FY26 with revenue growing 22% YoY to ₹1,388 crores, driven by robust performance in North America and Europe. EBITDA increased 34% to ₹308 crores, with margins expanding to 22.2% despite a ₹24.8 crore loss in the nascent Peptide CDMO segment. The company is making steady progress on regulatory remediation at its Gagillapur facility, following a constructive meeting with the US FDA in January 2026. Additionally, shareholders have approved a preferential issue to strengthen the balance sheet and fund future capacity expansions.

Revenue grew 22% YoY to ₹1,388 crores, while EBITDA rose 34% to ₹308 crores.
Gross margins improved by 216 bps YoY to 63.9% due to a better product mix in finished dosages.
Gagillapur remediation is on track with no concerns raised by the FDA regarding the pace of corrective actions.
Net debt stood at ₹1,015 crores with a cash-to-cash cycle of 202 days.
Peptide CDMO business (Ascelis) is expected to see meaningful improvement in Q4 FY26 following project deliveries.

💡 Investors should monitor the final resolution of the Gagillapur warning letter and the commercial scale-up of the high-margin Peptide CDMO business. The company's focus on complex generics and integrated manufacturing continues to drive operational leverage.

Granules India Q3FY26: Revenue Up 22% YoY to ₹13,879 Mn, PAT Grows 28%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 09:45 PM

Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and scaling of the complex generics portfolio. The company maintained a healthy ROCE of 16.8% and reduced its Net Debt/EBITDA ratio to 0.91x.

Revenue increased 22% YoY to ₹13,879 Mn, with Europe sales surging 131% YoY to ₹2,344 Mn.
EBITDA grew 34% YoY to ₹3,081 Mn, with margins improving to 22.2% from 20.2% in the previous year.
Finished Dosage (FD) segment continues to dominate, contributing 76% of total revenue.
Complex generics portfolio expanded, driven by the scale-up of the ADHD portfolio in the US market.
US Packaging facility completed FDA inspection with zero observations, and ANVISA Brazil GMP certificate was received for the Gagillapur site.

💡 The company's strategic shift toward complex generics and finished dosages is yielding higher margins and robust growth. Investors should maintain a positive outlook given the strong regulatory compliance record and expanding presence in high-value markets like Europe.

Granules India Q3FY26 PAT Rises 28% YoY to ₹1,502 Mn; EBITDA Margins Expand to 22.2%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 05:11 PM

Granules India reported a strong Q3FY26 with revenue growing 22% YoY to ₹13,879 Mn, primarily driven by the Finished Dosage segment in North America and Europe. EBITDA margins expanded by 196 bps YoY to 22.2%, despite an EBITDA loss of ₹248 Mn from the Ascelis Peptides business. Net profit increased 28% YoY to ₹1,502 Mn, supported by a better product mix and operational efficiencies. The company also received a credit rating upgrade from ICRA to AA and reported zero observations for its US packaging facility.

Revenue increased 22% YoY to ₹13,879 Mn, led by 131% growth in the European market.
EBITDA grew 34% YoY to ₹3,081 Mn with margins improving to 22.2% from 20.2% last year.
Finished Dosage (FD) segment remains the primary driver, contributing 76% of total revenue.
ICRA upgraded the company's credit rating from AA- to AA, reflecting improved financial stability.
R&D investment stood at ₹689 Mn (5% of sales), focusing on complex generics and oncology.

💡 The stock shows strong fundamental growth with margin expansion and a successful shift towards high-margin complex generics. Investors should maintain a positive outlook while monitoring the break-even timeline for the Peptides business.

Granules India Q3FY26 PAT Rises 28% YoY to INR 1,502 Mn; Revenue Up 22%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 23 Jan 2026, 05:09 PM

Granules India reported a strong Q3FY26 performance with revenue growing 22% YoY to INR 13,879 Mn, primarily driven by the Finished Dosages segment in North America and Europe. Profitability improved significantly as EBITDA rose 34% YoY to INR 3,081 Mn, with margins expanding to 22% from 20% in the previous year. Net profit (PAT) increased 28% YoY to INR 1,502 Mn, reflecting efficient execution and vertical integration. The company maintains a healthy balance sheet with a Net Debt to EBITDA ratio of 0.91x and a ROCE of 16.8%.

Revenue from operations grew 22% YoY to INR 13,879 Mn, led by Finished Dosages which contributes 76% of total revenue.
EBITDA increased 34% YoY to INR 3,081 Mn, with margins improving to 22%.
PAT grew 28% YoY to INR 1,502 Mn, showing strong bottom-line momentum.
Net Debt to EBITDA remains conservative at 0.91x with total net debt at INR 10,151 Mn.
ROCE stood at 16.8% post the acquisition of Senn Chemicals AG, compared to 16.4% YoY.

💡 The company's strong operational momentum and margin expansion in regulated markets like North America and Europe are positive indicators. Investors should monitor the scaling of the Peptides/CDMO segment and the continued integration of Senn Chemicals for long-term value.

Granules India Q3 FY26 Net Profit Rises 23.8% YoY to ₹1,115.8M; Plans ₹17,625M Fundraising

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 23 Jan 2026, 05:05 PM

Granules India reported a 6.3% YoY increase in standalone revenue to ₹8,953.18 million for Q3 FY26, with net profit growing 23.8% to ₹1,115.82 million. The company is navigating challenges from a USFDA warning letter at its Gagillapur facility, which has led to higher remediation costs and production slowdowns. A significant fundraising plan of approximately ₹17,625 million through warrants and equity at ₹585 per share has been approved to support growth. Additionally, the company completed the acquisition of Granules Pharmaceuticals GmbH in Germany and accounted for costs related to the Senn Chemicals AG acquisition.

Standalone Net Profit increased by 23.8% YoY to ₹1,115.82 million in Q3 FY26.
Total Revenue from operations grew 6.3% YoY to ₹8,953.18 million.
Approved fundraising of ₹14,625 million via convertible warrants and ₹3,000 million via equity at ₹585/share.
Exceptional item of ₹121.60 million recorded for Senn Chemicals AG acquisition costs.
Ongoing remediation at Gagillapur facility following USFDA warning letter continues to impact margins via higher consultancy and freight costs.

💡 Investors should monitor the progress of the USFDA remediation at the Gagillapur plant and the utilization of the ₹17,625 million fundraise. The growth in profit despite regulatory hurdles is a positive sign, but the high remediation costs remain a near-term drag.

Granules India Shareholders Approve Issuance of 2.5 Crore Warrants and 51.28 Lakh Equity Shares

🟢 POSITIVE ⭐ 8/10

FUNDRAISE 📅 22 Jan 2026, 05:12 PM

Granules India Limited held an Extraordinary General Meeting (EGM) on January 22, 2026, where shareholders approved two significant capital-raising resolutions. The first resolution involves the issuance of up to 2.5 crore warrants convertible into equity shares on a preferential basis, which passed with 86.69% support. The second resolution for the issuance of up to 51.28 lakh equity shares on a preferential basis received near-unanimous approval at 99.99%. These approvals provide the company with a mandate to raise capital through preferential allotments, likely aimed at funding future growth or strategic initiatives.

Approved issuance of up to 2,50,00,000 warrants convertible into equity shares on a preferential basis.
Approved issuance of up to 51,28,205 equity shares on a preferential basis.
Warrant resolution passed with 86.69% majority, while the equity share resolution saw 99.99% approval.
A total of 73 shareholders participated in the meeting held via video conferencing.
The voting results were consolidated from both remote e-voting and e-voting during the EGM.

💡 Investors should look for subsequent disclosures regarding the allotment price and the specific identity of the allottees to assess potential equity dilution. The successful passage of these resolutions indicates strong shareholder backing for the company's capital expansion plans.

Granules India Issues Corrigendum for Rs 1,762.5 Cr Fundraise; Re-allocates Shares to 360 ONE Funds

🟡 NEUTRAL ⭐ 7/10

FUNDRAISE 📅 13 Jan 2026, 11:18 AM

Granules India has issued a corrigendum to its EGM notice regarding a preferential issue of equity shares and warrants totaling approximately Rs 1,762.5 crore. The primary change involves the removal of the Public Sector Pension Investment Board from the allottee list, with their portion re-allocated to various 360 ONE funds. The total issue size remains unchanged, and the proceeds are earmarked for capital expenditure, debt prepayment for its subsidiary Granules Life Sciences, and working capital. India Ratings & Research has been appointed as the monitoring agency for the fund utilization.

Total fundraise size remains unchanged at approximately Rs 1,762.5 crore via equity and warrants.
Public Sector Pension Investment Board removed as an allottee; shares re-allocated to 360 ONE funds.
Rs 315 crore allocated for prepayment of term loans for subsidiary Granules Life Sciences Private Limited.
Rs 300 crore designated for capital expenditure in fixed assets, infrastructure, and technology over 24 months.
India Ratings & Research Private Limited appointed as the monitoring agency for issue proceeds.

💡 Investors should monitor the EGM outcome on January 22, 2026, as the capital infusion will significantly reduce debt and fund expansion. The re-allocation to 360 ONE funds indicates continued strong institutional interest despite the removal of one specific allottee.

Granules India Schedules Q3 FY26 Earnings Conference Call for January 23, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Jan 2026, 10:36 AM

Granules India Limited has announced its earnings conference call to discuss the financial results for the third quarter and nine months ended December 31, 2025 (Q3 FY26). The call is scheduled for Friday, January 23, 2026, at 6:00 PM IST. Key management personnel, including the Chairman & MD, CFO, and CTO, will be present to provide business updates and address investor queries. This is a standard regulatory filing following SEBI Listing Obligations and Disclosure Requirements.

Earnings conference call scheduled for January 23, 2026, at 18:00 IST
Management participants include Chairman & MD Dr. Krishna Prasad Chigurupati and CFO Mukesh Surana
Call will cover financial performance for Q3 and 9M FY26 and general business updates
Primary dial-in numbers are +91 22 6280 1550 and +91 22 7115 8378

💡 Investors should mark the date to listen for management commentary on margin sustainability and the progress of the company's backward integration strategy. No immediate action is required as this is a routine scheduling announcement.

Granules Gets US FDA Tentative Approval for Generic Dyanavel XR with 180-Day Exclusivity

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 08 Jan 2026, 08:30 AM

Granules India's US subsidiary has received tentative FDA approval for generic Amphetamine Extended-Release tablets, the generic version of DYANAVEL XR, used for ADHD treatment. Significantly, the company has secured 180-day exclusivity for this product, which addresses a market size of approximately USD 41 million. This marks the second major CNS-related tentative approval in weeks, following a December 2025 approval for a generic version of ADZENYS XR-ODT with a USD 172 million market. These developments highlight the company's successful pivot toward complex generics and differentiated products in the U.S. market.

Received US FDA Tentative Approval for generic Amphetamine ER tablets (gDYANAVEL XR) in 5mg, 10mg, 15mg, and 20mg strengths.
Granted 180-day exclusivity by the FDA, ensuring a period of limited competition upon commercial launch.
Targets an addressable market size of approximately USD 41 million for the gDYANAVEL XR equivalent.
Follows a recent tentative approval for generic ADZENYS XR-ODT which has a USD 172 million market potential.
Strengthens Granules' portfolio in the complex Central Nervous System (CNS) therapeutic segment.

💡 Investors should monitor the transition from tentative to final approval and the subsequent launch timeline, as the 180-day exclusivity provides a high-margin opportunity. The company's growing pipeline of complex generics suggests a positive shift in its product mix toward higher-value segments.

Granules India to Raise ₹1,762.50 Cr via Preferential Issue of Warrants and Equity Shares

🟢 POSITIVE ⭐ 9/10

FUNDRAISE 📅 31 Dec 2025, 01:28 PM

Granules India has scheduled an Extraordinary General Meeting on January 22, 2026, to approve a total fundraise of ₹1,762.50 crores. The company plans to issue 2.5 crore convertible warrants to the promoter group at ₹585 each, totaling ₹1,462.50 crores. Additionally, it will issue 51.28 lakh equity shares at the same price to institutional investors, including 360 ONE funds and the Public Sector Pension Investment Board, raising ₹300 crores. This significant capital infusion, largely backed by promoters, indicates strong internal confidence in the company's growth trajectory.

Issuance of 2.5 crore warrants to the promoter group at ₹585 per warrant, totaling ₹1,462.50 crores.
Preferential allotment of 51.28 lakh equity shares to institutional investors at ₹585 per share, raising ₹300 crores.
Total capital infusion of ₹1,762.50 crores to be approved at the EGM on January 22, 2026.
Warrant terms require 25% payment upfront with the remaining 75% payable upon conversion within 18 months.
Key institutional participants include various 360 ONE funds and the Public Sector Pension Investment Board.

💡 Investors should take the significant promoter participation as a positive signal of long-term commitment and confidence. Monitor upcoming disclosures regarding the specific utilization of these funds for expansion or debt reduction.

Granules India Announces Trading Window Closure from January 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 10:06 AM

Granules India Limited has informed the stock exchanges that its trading window will be closed starting January 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure applies to all designated persons and their immediate relatives to prevent insider trading ahead of financial disclosures. The window will remain shut until 48 hours after the declaration of the unaudited financial results for the quarter and nine months ending December 31, 2025.

Trading window closure effective from January 1, 2026.
Closure pertains to the financial results for the quarter and nine months ending December 31, 2025.
Restriction applies to all insiders, designated persons, and their immediate relatives.
Trading window will reopen 48 hours after the official announcement of the financial results.

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should focus on the upcoming quarterly results for performance insights.

View All GRANULES Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

In Q2 FY26, Finished Dosages (FD) grew 29% YoY to INR 965.7 Cr (74% of revenue). Pharmaceutical Formulation Intermediates (PFI) grew 76% YoY to INR 133.1 Cr (10% share). Active Pharmaceutical Ingredients (API) grew 20% YoY to INR 170.5 Cr (13% share). Peptides/CDMO contributed INR 27.6 Cr (2% share).

Geographic Revenue Split

North America remains the largest market at 76% of revenue (INR 988.2 Cr), growing 30% YoY. Europe contributed 12% (INR 152.8 Cr), growing 66% YoY. Rest of World (ROW) contributed 12% (INR 155.9 Cr), growing 37% YoY.

Profitability Margins

Gross Margin expanded 82 bps YoY to 65.7% in Q2 FY26 due to improved product mix and operational efficiency. PAT margin stood at 10.1% (INR 130.6 Cr), up 34% YoY from INR 97.2 Cr.

EBITDA Margin

EBITDA margin was 21.5% in Q2 FY26, an improvement of 42 bps YoY and 106 bps QoQ. Absolute EBITDA rose 37% YoY to INR 278.2 Cr, despite an EBITDA loss of INR 20 Cr from the Ascelis Peptides acquisition.

Capital Expenditure

CAPEX spend in Q2 FY26 was INR 211.2 Cr, significantly higher than INR 113.7 Cr in Q1 FY26. Total planned CAPEX for FY2025 is approximately INR 600 Cr, focusing on scaling up the CDMO business and facility upgrades.

Credit Rating & Borrowing

ICRA maintains an adequate liquidity profile with cash balances of INR 381.1 Cr as of March 2024. Net Debt stood at INR 1,024.1 Cr in Q2 FY26 with a Net Debt/EBITDA ratio of 0.98x. Term loan repayments are scheduled at INR 100 Cr for FY25 and INR 50 Cr for FY26.

⚙️ Operational Drivers

Raw Materials

Key starting materials (KSMs) for core APIs including Paracetamol, Ibuprofen, Metformin, Methocarbamol, and Guaifenesin. These five products historically represent a significant portion of revenue, with 4 out of 5 being backward integrated.

Import Sources

Sourced globally with significant backward integration in India (Gagillapur and Bonthapally facilities) to mitigate supply chain volatility from external markets like China.

Key Suppliers

Not specifically named in documents, but the company utilizes a mix of internal manufacturing for 4/5 key APIs and external vendors for specialized KSMs.

Capacity Expansion

Operates 11 manufacturing facilities (8 in India, 2 in USA, 1 in Switzerland). Recent expansion includes a new subsidiary, Granules Pharmaceuticals Canada, Inc., and the acquisition of Senn Chemicals AG for CDMO capacity.

Raw Material Costs

Raw material costs are managed through vertical integration, maintaining operating margins between 18-20%. Gross margins improved to 65.7% in Q2 FY26 due to better operational efficiency and product mix.

Manufacturing Efficiency

Productivity improvements at the Gagillapur facility and the start of monograph product manufacturing at Genome Valley have enhanced throughput. Fixed Asset Turn stood at 1.46 in Q2 FY26.

Logistics & Distribution

Distribution spans 300+ customers in 80+ countries. The US front-end division (Granules Consumer Health) leverages integrated supply chains to improve OTC product margins.

📈 Strategic Growth

Expected Growth Rate

15-20%

Growth Strategy

Growth will be driven by scaling the CDMO business (Senn Chemicals), expanding the peptide portfolio (Ascelis), and entering the Canadian market. The company is also gaining market share in existing products approved 2-3 years ago and expects a revenue boost once the Gagillapur facility clears its US FDA warning letter.

Products & Services

Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), Peptides, and CDMO services for innovators.

Brand Portfolio

Granules India, Granules Consumer Health, Senn Chemicals, Ascelis Peptides.

New Products/Services

Focus on controlled substances, OTC products, and monograph products from Genome Valley. 3 ANDAs were filed in Q2 FY26, adding to 91 total US FDA approvals.

Market Expansion

Incorporated Granules Pharmaceuticals Canada, Inc. in November 2025 to target the Canadian prescription generic market. Continued penetration in LATAM and Europe for PFI and FD segments.

Market Share & Ranking

One of the few global players present across the entire pharmaceutical value chain. Gaining share in US generic markets through long-term product positioning.

Strategic Alliances

CDMO partnerships where Granules acts as a 'co-traveler' with innovators on long-term projects (FY27-FY28 horizon).

🌍 External Factors

Industry Trends

The industry is shifting toward specialized CDMO services and complex molecules like peptides. Granules is positioning itself by moving from high-volume generics to value-added CDMO and peptide manufacturing.

Competitive Landscape

Faces intense competition in the generic space from other Indian and global pharma majors, mitigated by high-volume manufacturing efficiencies.

Competitive Moat

Moat is built on 'cost leadership through vertical integration' and 'regulatory excellence.' Being present from API to FD allows for superior margin control compared to non-integrated peers.

Macro Economic Sensitivity

Sensitive to Indian and international interest rates and changes in foreign exchange control regulations in India.

Consumer Behavior

Increasing demand for OTC products in the US market, which Granules is capturing through its front-end division and zero-observation packaging facilities.

Geopolitical Risks

Changes in political conditions in India or destination countries and evolving global pharmaceutical regulations pose risks to the 80+ countries of operation.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by US FDA, EDQM, EU GMP, and WHO GMP. The Gagillapur facility is currently undergoing remediation following a US FDA inspection in August 2024.

Environmental Compliance

Achieved 'A' rating in CDP Climate Change (2025), reflecting a two-level improvement. Invests in ESG to meet global standards required by international partners.

Taxation Policy Impact

Subject to Indian corporate tax rates and international tax laws for subsidiaries in the US, Switzerland, and Canada.

Legal Contingencies

The company faces industry-wide social risks related to product safety litigation and high manufacturing compliance standards. A US FDA warning letter for Gagillapur is the primary active regulatory hurdle.

⚠️ Risk Analysis

Key Uncertainties

The timeline for the US FDA re-inspection of the Gagillapur facility (scheduled for January 2026) is a major uncertainty that could delay new product launches.

Geographic Concentration Risk

High concentration in North America (76% of revenue), making the company highly sensitive to US regulatory changes and generic pricing dynamics.

Third Party Dependencies

While vertically integrated for 4/5 key APIs, the company still depends on external suppliers for specialized KSMs and chemicals for its CDMO division.

Technology Obsolescence Risk

Risk of digital disruption and information security incidents (similar to the one in FY2024). Mitigation involves continuous R&D (5.4% of sales) and IT infrastructure upgrades.

Credit & Counterparty Risk

Adequate liquidity and a Net Debt/EBITDA of 0.98x suggest low credit risk, though working capital intensity (204-day cycle) requires constant monitoring.